Effects of Glucan and Vitamin D Supplementation on Obesity and Lipid Metabolism in Diabetic Retinopathy
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené arabské emiráty Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
29760812
PubMed Central
PMC5897984
DOI
10.2174/1874091x01812010036
PII: TOBIOCJ-12-36
Knihovny.cz E-zdroje
- Klíčová slova
- Clinical trials, Diabetes, Diabetic retinopathy, Glucan, Obesity, Supplementation, Vitamin D,
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Diabetes mellitus is a chronic disease manifested by an increase of blood glucose. OBJECTIVE: To evaluate the effects of glucan and vitamin D supplementation in patients with diabetic retinopathy. METHOD: We evaluated the effects of 3-month supplementation with glucan and vitamin D in 54 patients with diabetic retinopathy. We measured levels of vitamin D, cholesterol, HDL cholesterol, and triglycerides. RESULTS: The supplementation strongly decreased the cholesterol levels and improved the levels of HDL cholesterol. In addition, vitamin D levels were strongly improved, but still not at optimal values. CONCLUSION: From our data, we concluded that glucan and vitamin D supplementation strongly influence lipid metabolism and have positive effects on human health.
Health Institute with headquarters in Usti and Labem Usti and Labem Czech Republic
Official Clinic of UJEP Masaryk Hospital Regional Health Usti and Labem Czech Republic
University of Louisville Department of Pathology Louisville KY USA
Zobrazit více v PubMed
Kowluru R.A., Zhong Q., Santos J.M., Thandampallayam M., Putt D., Gierhart D.L. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr. Metab. (Lond.) 2014;11(1):8. doi: 10.1186/1743-7075-11-8. PubMed DOI PMC
Fahey J.W., Wade K.L., Wehage S.L., Holtzclaw W.D., Liu H., Talalay P., Fuchs E., Stephenson K.K. Stabilized sulforaphane for clinical use: Phytochemical delivery efficiency. Mol. Nutr. Food Res. 2017;61(4):61. doi: 10.1002/mnfr.201600766. PubMed DOI
Yamagishi S., Matsui T. Protective role of sulphoraphane against vascular complications in diabetes. Pharm. Biol. 2016;54(10):2329–2339. doi: 10.3109/13880209.2016.1138314. PubMed DOI
Zhou Y., Zhang Y., Shi K., Wang C. Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review. Medicine (Baltimore) 2017;96(22):e6754. doi: 10.1097/MD.0000000000006754. PubMed DOI PMC
Atchison E., Barkmeier A. The role of systemic risk factors in diabetic retinopathy. Curr. Ophthalmol. Rep. 2016;4(2):84–89. doi: 10.1007/s40135-016-0098-8. PubMed DOI PMC
Cloetens L., Ulmius M., Johansson-Persson A., Akesson B., Onning G. Role of dietary beta-glucans in the prevention of the metabolic syndrome. Nutr. Rev. 2012;70(8):444–458. doi: 10.1111/j.1753-4887.2012.00494.x. PubMed DOI
Friedman M. Mushroom polysaccharides: Chemistry and antiobesity, antidiabetes, anticancer, and antibiotic aroperties in cells, rodents, and humans. Foods. 2016;5(4):5. doi: 10.3390/foods5040080. PubMed DOI PMC
Maki K.C., Beiseigel J.M., Jonnalagadda S.S., Gugger C.K., Reeves M.S., Farmer M.V., Kaden V.N., Rains T.M. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J. Am. Diet. Assoc. 2010;110(2):205–214. doi: 10.1016/j.jada.2009.10.037. PubMed DOI
Touvier M., Deschasaux M., Montourcy M., Sutton A., Charnaux N., Kesse-Guyot E., Assmann K.E., Fezeu L., Latino-Martel P., Druesne-Pecollo N., Guinot C., Latreille J., Malvy D., Galan P., Hercberg S., Le Clerc S., Souberbielle J.C., Ezzedine K. Determinants of vitamin D status in Caucasian adults: influence of sun exposure, dietary intake, sociodemographic, lifestyle, anthropometric, and genetic factors. J. Invest. Dermatol. 2015;135(2):378–388. doi: 10.1038/jid.2014.400. PubMed DOI
Jesch E.D., Carr T.P. Food ingredients that inhibit cholesterol absorption. Prev. Nutr. Food Sci. 2017;22(2):67–80. PubMed PMC
Novak M., Vetvicka V. Glucans as biological response modifiers. Endocr. Metab. Immune Disord. Drug Targets. 2009;9(1):67–75. doi: 10.2174/187153009787582423. PubMed DOI
Richter J., Svozil V., Král V., Rajnohová Dobiášová L., Stiborová I., Vetvicka V. Clinical trials of yeast-derived β-(1,3) glucan in children: effects on innate immunity. Ann. Transl. Med. 2014;2(2):15. PubMed PMC
Sima P., Vannucci L., Vetvicka V. Glucans and cancer: Historical perspective. Cancer Transl. Med. 2015;1:209–214. doi: 10.4103/2395-3977.172860. DOI
Vetvicka V. Nova Biomedical, New York; 2013. b-Glucans as natural biological response modifiers.
Vetvicka V. Vol. 2. Int Clin Pathol J; 2013. V, J. Why So Many Glucans? .
El Khoury D., Cuda C., Luhovyy B.L., Anderson G.H. Beta glucan: health benefits in obesity and metabolic syndrome. J. Nutr. Metab. 2012;2012:851362. doi: 10.1155/2012/851362. PubMed DOI PMC
Guo L., Tong L.T., Liu L., Zhong K., Qiu J., Zhou S. The cholesterol-lowering effects of oat varieties based on their difference in the composition of proteins and lipids. Lipids Health Dis. 2014;13:182. doi: 10.1186/1476-511X-13-182. PubMed DOI PMC
Queenan K.M., Stewart M.L., Smith K.N., Thomas W., Fulcher R.G., Slavin J.L. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr. J. 2007;6:6. doi: 10.1186/1475-2891-6-6. PubMed DOI PMC
Whitehead A., Beck E.J., Tosh S., Wolever T.M. Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2014;100(6):1413–1421. doi: 10.3945/ajcn.114.086108. PubMed DOI PMC
Vetvicka V., Vancikova Z. Anti-stress action of several orally-given β-glucans. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2010;154(3):235–238. doi: 10.5507/bp.2010.035. PubMed DOI
Vetvicka V., Vetvickova J. Anti-stress action of an orally-given combination of resveratrol, β-glucan, and vitamin C. Molecules. 2014;19(9):13724–13734. doi: 10.3390/molecules190913724. PubMed DOI PMC
Krakauer N.Y., Krakauer J.C. A new body shape index predicts mortality hazard independently of body mass index. PLoS One. 2012;7(7):e39504. doi: 10.1371/journal.pone.0039504. PubMed DOI PMC
Organization W.H. World Health Organization; 2011. Waist Circumference and waist-hip ratio, Report of a WHO expert consultation,Geneva. pp. 8–11.
Wang S., Liu Y., Li F., Jia H., Liu L., Xue F. A novel quantitative body shape score for detecting association between obesity and hypertension in China. BMC Public Health. 2015;15:7. doi: 10.1186/s12889-014-1334-5. PubMed DOI PMC
Pannu P.K., Piers L.S., Soares M.J., Zhao Y., Ansari Z. Vitamin D status is inversely associated with markers of risk for type 2 diabetes: A population based study in Victoria, Australia. PLoS One. 2017;12(6):e0178825. doi: 10.1371/journal.pone.0178825. PubMed DOI PMC
Čapková N. Selected Population Health Indicators in the Czech Republic-EHES 2014. Hygiena. 2017;2017:35–37. doi: 10.21101/hygiena.a1511. DOI
Kubínová R. Public Health Institute Praha; 2016. National Health Observatory in the Czech Republic.
Talbott S.M., Talbott J.A. Baker’s yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. J. Am. Coll. Nutr. 2012;31(4):295–300. doi: 10.1080/07315724.2012.10720441. PubMed DOI
Brown L., Rosner B., Willett W.W., Sacks F.M. Cholesterol-lowering effects of dietary fiber: A meta-analysis. Am. J. Clin. Nutr. 1999;69(1):30–42. doi: 10.1093/ajcn/69.1.30. PubMed DOI
Ho H.V., Sievenpiper J.L., Zurbau A., Blanco Mejia S., Jovanovski E., Au-Yeung F., Jenkins A.L., Vuksan V. The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br. J. Nutr. 2016;116(8):1369–1382. doi: 10.1017/S000711451600341X. PubMed DOI
Vetvicka V., Vetvickova J. Effects of yeast-derived beta-glucans on blood cholesterol and macrophage functionality. J. Immunotoxicol. 2009;6(1):30–35. doi: 10.1080/15476910802604317. PubMed DOI
Jenkins D.J., Kendall C.W., Axelsen M., Augustin L.S., Vuksan V. Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. Curr. Opin. Lipidol. 2000;11(1):49–56. doi: 10.1097/00041433-200002000-00008. PubMed DOI
Caz V., Gil-Ramírez A., Largo C., Tabernero M., Santamaría M., Martín-Hernández R., Marín F.R., Reglero G., Soler-Rivas C. Modulation of cholesterol-related gene expression by dietary fiber fractions from edible mushrooms. J. Agric. Food Chem. 2015;63(33):7371–7380. doi: 10.1021/acs.jafc.5b02942. PubMed DOI
Lim M.K., Ku S.K., Choi J.S., Kim J.W. Effect of polycan, a β-glucan originating fromAureobasidium,on a high-fat diet-induced hyperlipemic hamster model. Exp. Ther. Med. 2015;9(4):1369–1378. doi: 10.3892/etm.2015.2238. PubMed DOI PMC
Wu Y.S., Ho S.Y., Nan F.H., Chen S.N. Ganoderma lucidum beta 1,3/1,6 glucan as an immunomodulator in inflammation induced by a high-cholesterol diet. BMC Complement. Altern. Med. 2016;16(1):500. doi: 10.1186/s12906-016-1476-3. PubMed DOI PMC
Kusmiati, Dhewantara F.X. Cholesterol-lowering effect of beta glucan extracted from Saccharomyces cerevisiae in rats. Sci. Pharm. 2016;84(1):153–165. doi: 10.3797/scipharm.ISP.2015.07. PubMed DOI PMC
Anderson J.W., Gustafson N.J. Hypocholesterolemic effects of oat and bean products. Am. J. Clin. Nutr. 1988;48(3) Suppl.:749–753. doi: 10.1093/ajcn/48.3.749. PubMed DOI
Anderson J.W., Story L., Sieling B., Chen W.J., Petro M.S., Story J. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am. J. Clin. Nutr. 1984;40(6):1146–1155. doi: 10.1093/ajcn/40.6.1146. PubMed DOI
Braaten J.T., Wood P.J., Scott F.W., Wolynetz M.S., Lowe M.K., Bradley-White P., Collins M.W. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur. J. Clin. Nutr. 1994;48(7):465–474. PubMed
Mehmood Z.H., Papandreou D. An updated mini review of vitamin D and obesity: Adipogenesis and inflammation state. Open Access Maced. J. Med. Sci. 2016;4(3):526–532. doi: 10.3889/oamjms.2016.103. PubMed DOI PMC